Ja Nean Reay (Ciedro) Email: jciedro@pitt.edu Lab: Robbins Lab Recombinant or adenovirally delivered IL-12 exhibits potent anti-tumor activity in various mouse models of cancer by inhibiting tumor establishment, causing regression of established tumors, and inducing tumor specific protective immunity. However IL-12 treatment is associated with severe toxicity. Novel IL-12 family members, IL-23 and IL-27, are expected to share much of the immunostimulatory and anti-tumor activities of IL-12. We are currently investigating the anti-tumor activities of adenovirally delivered IL-23 and IL-27 in a mouse model of fibrosarcoma and elucidating their mechanism of action. Once the anti-tumor activities of these cytokines have been established, the ability of these cytokines to synergize with IL-12 to enhance induction of anti-tumor immunity and reduce IL-12 associated toxicity will be investigated.